Aerovate Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Tim Noyes

İcra Kurulu Başkanı

US$3.1m

Toplam tazminat

CEO maaş yüzdesi	19.1%
CEO görev süresi	3.5yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3yrs
Yönetim Kurulu ortalama görev süresi	3.5yrs

Son yönetim güncellemeleri

Recent updates

Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely

Oct 01

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Jun 11

Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

May 24

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Feb 09

We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Oct 17

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Jul 04

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Feb 28

A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Jan 06

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Oct 14

Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

Jul 01

We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Jan 22

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Sep 30

CEO Tazminat Analizi

Tim Noyes'un ücretlendirmesi Aerovate Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$85m
Jun 30 2024	n/a	n/a	-US$88m
Mar 31 2024	n/a	n/a	-US$82m
Dec 31 2023	US$3m	US$586k	-US$76m
Sep 30 2023	n/a	n/a	-US$70m
Jun 30 2023	n/a	n/a	-US$64m
Mar 31 2023	n/a	n/a	-US$57m
Dec 31 2022	US$704k	US$563k	-US$52m
Sep 30 2022	n/a	n/a	-US$45m
Jun 30 2022	n/a	n/a	-US$37m
Mar 31 2022	n/a	n/a	-US$31m
Dec 31 2021	US$5m	US$437k	-US$23m

Tazminat ve Piyasa: Tim 'nin toplam tazminatı ($USD 3.07M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 649.07K ).

Tazminat ve Kazançlar: Tim şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Tim Noyes (62 yo)

3.5yrs

Görev süresi

US$3,070,657

Tazminat

Mr. Timothy P. Noyes, MBA, also known as Tim, has been the Chief Executive Officer of Aerovate Therapeutics, Inc. since May 2021 and has been its Director since April 2021. Mr. Noyes serves as Venture Part...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Timothy Noyes	CEO & Director	3.5yrs	US$3.07m	Veri yok
George Eldridge	CFO & Treasurer	3.7yrs	US$2.13m	0.017% $ 13.4k
Benjamin Dake	Founder	6.3yrs	US$2.88m	0.049% $ 37.9k
Ralph Niven	Chief Scientific Officer	2.3yrs	US$433.20k	0.0056% $ 4.3k
Hunter Gillies	Chief Medical Officer	4.5yrs	US$1.63m	0.019% $ 14.9k
Donna Dea	Head of Regulatory Affairs	4.2yrs	Veri yok	Veri yok
Susan Fischer	Executive Vice President of Development Operations	2.6yrs	Veri yok	Veri yok
Stephen Yu	Senior Vice President of Quality	2.3yrs	Veri yok	Veri yok
Sanjeev Khindri	Executive Vice President of Clinical Development	1.8yrs	Veri yok	Veri yok
Cheryl Lassen	Senior Vice President of Clinical Development	1.8yrs	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: AVTE 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Timothy Noyes	CEO & Director	3.6yrs	US$3.07m	Veri yok
Christian Schade	Independent Director	1.3yrs	Veri yok	Veri yok
Donald Santel	Independent Director	1.8yrs	US$568.54k	0% $ 0
David Grayzel	Independent Director	4.3yrs	US$225.99k	0% $ 0
Joshua Resnick	Independent Director	4.3yrs	US$174.80k	0% $ 0
Mark Iwicki	Independent Director	3.8yrs	US$218.30k	0% $ 0
Allison Dorval	Independent Director	3.3yrs	US$185.80k	0% $ 0
Habib Dable	Independent Chairman of the Board	1.3yrs	US$363.25k	0% $ 0

3.5yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AVTE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).

Aerovate Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aerovate Therapeutics, Inc. Approves the Appointment of Habib J. Dable as Member of the Audit Committee

Aerovate Therapeutics, Inc. Announces Resignation of Maha Katabi as Board of Directors and Member of Audit Committee and Compensation Committee

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Aerovate Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

CFO & Treasurer exercised options and sold US$185k worth of stock

Recent updates

Jade Biosciences, Inc. entered into a definitive merger agreement to acquire Aerovate Therapeutics, Inc. (NasdaqGM:AVTE) in a reverse merger transaction.

Jade Biosciences, Inc. entered into a definitive merger agreement to acquire Aerovate Therapeutics, Inc. (NasdaqGM:AVTE) in a reverse merger transaction.

Aerovate Therapeutics Provides Update on Nasdaq Audit Committee Compliance

Aerovate Therapeutics, Inc. Approves the Appointment of Habib J. Dable as Member of the Audit Committee

Aerovate Therapeutics, Inc. Announces Resignation of Maha Katabi as Board of Directors and Member of Audit Committee and Compensation Committee

Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2B Portion of Impahct Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Aerovate Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

CFO & Treasurer exercised options and sold US$185k worth of stock

Founder exercised options and sold US$192k worth of stock

Price target increased by 24% to US$39.67

CFO & Treasurer notifies of intention to sell stock

Aerovate Therapeutics, Inc. Announces Board Changes

Chief Medical Officer notifies of intention to sell stock

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$213k worth of stock

New major risk - Revenue and earnings growth

Chief Scientific Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2B Portion and Enrollment of First Patient into Phase 3 in the Impahct Trial Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension

We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Founder notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Aerovate Therapeutics, Inc. Appoints Habib Dable as Member of Board of Directors

CEO & Director notifies of intention to sell stock

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director exercised options and sold US$259k worth of stock

CEO & Director exercised options and sold US$325k worth of stock

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

CEO & Director exercised options and sold US$308k worth of stock

Aerovate Therapeutics, Inc. Appoints Donald Santel To Its Board of Directors

CEO & Director exercised options and sold US$374k worth of stock

A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Price target increased to US$33.25

CEO & Director exercised options and sold US$238k worth of stock

CFO & Treasurer notifies of intention to sell stock

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

High number of new and inexperienced directors

Founder exercised options and sold US$420k worth of stock

Aerovate Therapeutics, Inc. Presents Novel Phase 2B/Phase 3 Impahct Trial Design At Chest Annual Meeting 2022

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Founder exercised options and sold US$325k worth of stock

Founder exercised options and sold US$154k worth of stock

Price target increased to US$26.00

Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell 2000 Growth Index

Aerovate Therapeutics, Inc. Announces New Executive Appointments

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

Aerovate Therapeutics, Inc., Annual General Meeting, Jun 21, 2022

High number of new and inexperienced directors

We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

High number of new and inexperienced directors

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Aerovate Therapeutics, Inc. has completed an IPO in the amount of $121.549988 million.

CEO Tazminat Analizi

CEO

Görev süresi